Montelukast (Singulair) - Uses and Doses

Mechanism of Action

Montelukast is a leukotriene receptor antagonist (LTRA) - specifically a CysLT1 (LTD4) receptor antagonist. It blocks cysteinyl leukotrienes produced by mast cells, eosinophils, and basophils in the airway, thereby reducing bronchoconstriction, bronchial reactivity, mucosal edema, and mucus hypersecretion. - Katzung's Basic and Clinical Pharmacology, 16th Ed.

FDA-Approved Indications

1. Asthma (Prophylaxis & Chronic Treatment)

Indication: Prophylaxis and chronic treatment of asthma (not for acute attacks)
Approved for patients ≥12 months of age
Less effective than low-dose inhaled corticosteroids (ICS), but preferred by many (especially parents of young children) due to oral route and ease of use
Useful in aspirin-exacerbated respiratory disease (AERD) - a condition combining asthma, chronic rhinosinusitis with nasal polyposis, and NSAID sensitivity (~5-10% of asthmatic patients)

2. Exercise-Induced Bronchoconstriction (EIB) - Prevention

Indication: Acute prevention of EIB
Approved for patients ≥6 years
Single dose taken at least 2 hours before exercise
Do not take an additional dose within 24 hours
If already taking montelukast daily for another indication, do not take an extra dose for EIB

3. Allergic Rhinitis

Seasonal allergic rhinitis (SAR): Approved for patients ≥2 years
Perennial allergic rhinitis (PAR): Approved for patients ≥6 months
Less effective than H1 antihistamines and intranasal glucocorticoids for rhinitis - used when other therapies fail or are not tolerated; more effective when combined with antihistamines - Harrison's Principles of Internal Medicine, 22nd Ed.

Dosing by Age and Indication

Age Group	Formulation	Dose
Adults & adolescents ≥15 years	10 mg film-coated tablet	Once daily (evening for asthma)
Children 6-14 years	5 mg chewable tablet	Once daily
Children 2-5 years	4 mg chewable tablet OR 4 mg granule packet	Once daily
Infants/children 6 months-2 years (PAR only)	4 mg granule packet	Once daily
Infants 1-12 months (asthma only)	4 mg granule packet	Once daily (evening)

Exercise-Induced Bronchoconstriction (EIB) Dosing:

Age	Dose	Timing
≥15 years	10 mg	≥2 hours before exercise
6-14 years	5 mg	≥2 hours before exercise

Do not take an additional dose within 24 hours of the previous dose.

Available Formulations

10 mg film-coated tablets
5 mg chewable tablets
4 mg chewable tablets
4 mg oral granule packets (can be mixed with soft food)

Place in Asthma Step Therapy

Per NAEPP guidelines (Harriet Lane Handbook, 23rd Ed.):

Step 2 (ages 0-4): Alternative controller - daily montelukast (when ICS is not preferred)
Steps 4-6 (ages 0-4): Alternative add-on to medium/high-dose ICS
In older children and adults: montelukast < ICS < LABA for EIB efficacy ranking

Important Safety Warning - Neuropsychiatric Events

In March 2020, the FDA issued a Boxed Warning (its most serious warning) for montelukast regarding serious neuropsychiatric adverse events:

Agitation, aggressive behavior, anxiousness
Dream abnormalities, hallucinations, insomnia
Irritability, restlessness, tremor
Suicidal thoughts and actions

Because of this risk, montelukast is now generally reserved for patients who have not responded adequately to other therapies (especially for allergic rhinitis). - Harriet Lane Handbook, 23rd Ed.; Harrison's Principles of Internal Medicine, 22nd Ed.

Key Pharmacological Points

Route: Oral only
Metabolism: Hepatic via CYP3A4 and CYP2C9; CYP3A4 inducers (rifampicin, phenobarbital) can reduce levels
Timing: Taken in the evening for asthma (aligns with nocturnal worsening of symptoms)
Not for acute attacks: Does not replace short-acting beta-agonists (SABAs) for rescue therapy
Granules: Can be mixed with applesauce, carrots, rice, or ice cream (not liquids other than breast milk/formula)

This is a shared conversation. Sign in to Orris to start your own chat.